The Pharmacogenomic Control of Clopidogrel Response in Acute Coronary Syndromes

急性冠脉综合征中氯吡格雷反应的药物基因组学控制

• 批准号: 8581390
• 负责人: Stuart Alexander Scott
• 金额: $ 19.45万
• 依托单位: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-08-01 至 2017-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8581390
• 关键词: ABCB1 gene; Accounting; Adoption; Advisory Committees; Aftercare; Alleles; American; Ancillary Study; Anticoagulants; Antiplatelet Drugs; Applications Grants; Aspirin; Award; Basic Science; Benchmarking; Biology; Blood Platelets; Candidate Disease Gene; Cardiology; Cardiovascular system; Caring; Clinical; Clinical Research; Clinical Sciences; Clinical Services; Clinical Trials; Clinical Trials Design; Clinical and Translational Science Awards; Collaborations; Committee Members; Complex; Cytochrome P450; DNA Sequence; Data; Data Analyses; Disease; Doctor of Medicine; Doctor of Philosophy; Drug Kinetics; Effectiveness; Enrollment; Environment; Enzymes; Epidemiologist; Equipment; Event; Faculty; Foundations; Frequencies; Funding; Future; Gene Frequency; Gene Mutation; Genes; Genetic; Genetic Polymorphism; Genetic Variation; Genetic screening method; Genomics; Genotype; Goals; Human Genetics; Hybrids; Institutes; Laboratories; Legal patent; Medical Genetics; Medicine; Mentored Patient-Oriented Research Career Development Award; Mentors; Mentorship; Meta-Analysis; Molecular; Network-based; Outcome; Outcomes Research; Patients; Pharmaceutical Preparations; Pharmacodynamics; Pharmacogenetics; Pharmacogenomics; Phenotype; Platelet aggregation; Play; Practice Guidelines; Principal Investigator; Programmed Instruction; Publications; Quality Control; Research; Research Personnel; Research Project Grants; Resistance; Resources; Risk; Role; Sampling; Science; Serious Adverse Event; Single Nucleotide Polymorphism; Stents; Testing; Thrombosis; Time; Training; Translational Research; Treatment Efficacy; Variant; Warfarin; acute coronary syndrome; base; career; career development; clinically relevant; clopidogrel; cohort; design; exome sequencing; experience; genetic variant; genome wide association study; genome-wide; loss of function; medical schools; next generation; novel; patient oriented; percutaneous coronary intervention; pharmacogenetic testing; programs; public health relevance; response; skills; standard of care; trait; uptake

DESCRIPTION (provided by applicant): CANDIDATE: Stuart A. Scott, Ph.D., is a clinical molecular geneticist in the Mount Sinai Genetic Testing Laboratory, certified by the American Board of Medical Genetics (ABMG), who has drawn on his training and experience in clinical and basic science to develop a research program focused on translational pharmacogenomics. His previous pharmacogenetics research centered on the anticoagulant warfarin and the antiplatelet clopidogrel, and he has co-authored clinical pharmacogenetic practice guidelines for both of these agents. He now seeks a focused four-year K23 Award to support 85% protected time from his clinical responsibilities to initiate a whole-exome sequencing pharmacogenomics research project with related career development as he completes his two-year Institutional KL2 Faculty Scholar award in translational science. CAREER DEVELOPMENT: The long-term goal of the Candidate is to become an independently funded Principal Investigator in the field of translational pharmacogenomics research. This goal will be accomplished through Clinical and Translational Science Award (CTSA)/Pharmacogenomics Research Network (PGRN)- based co-mentorship, collaboration, and the practical and didactic mechanisms outlined in this application. INSTITUTIONAL ENVIRONMENT: The Department of Genetics and Genomic Sciences at the Mount Sinai School of Medicine (MSSM) is a hybrid basic science and clinical department that offers a broad-based program of instruction, research, and clinical services in translational genetics and genomic sciences. The MSSM Institute for Genomics and Multiscale Biology is a central resource for all the equipment and computational support necessary to accomplish modern genomics research. As such, the institutional environment at MSSM is ideal for the proper execution of the studies outlined in this application. RESEARCH PROJECT: Dual antiplatelet therapy (DAPT) with clopidogrel and aspirin is standard of care for patients with acute coronary syndromes (ACS) and/or for those undergoing percutaneous coronary intervention (PCI)~ however, substantial interindividual variability in platelet inhibition and clinical response is commonly observed. Cytochrome P450-2C19 (CYP2C19) is a key enzyme involved in clopidogrel bioactivation and patients who carry CYP2C19 loss-of-function alleles have reduced therapeutic efficacy and increased risks for serious adverse cardiovascular events. However, CYP2C19 only accounts for ~12% of the variability in clopidogrel response. The proposed research project will use whole-exome sequencing and genome-wide genotyping in carefully selected extreme phenotype cohorts of DAPT-treated ACS/PCI patients to identify novel genetic variants, which could facilitate the adoption of genetically guided antiplatelet therapy into routine interventional cardiology practice for more personalized and effective care. The identification of additioal genes and variants will not only influence the uptake of personalized antiplatelet therapy, but could provide a benchmark for other pharmacogenomic studies on drugs and medications with variable responses.

描述（由申请人提供）： 候选人：斯图尔特A。斯科特博士， 是西奈山基因检测实验室的临床分子遗传学家，经美国医学遗传学委员会（ABMG）认证，他利用自己在临床和基础科学方面的培训和经验，开发了一个专注于转化药物基因组学的研究项目。他以前的药物遗传学研究集中在抗凝剂华法林和抗血小板氯吡格雷，他与人合著了这两种药物的临床药物遗传学实践指南。 他现在寻求一个集中的四年K23奖，以支持85%的保护时间，从他的临床责任，以启动一个全外显子组测序药物基因组学研究项目与相关的职业发展，因为他完成了他的为期两年的机构KL 2教师奖学金在转化科学奖。 职业发展：候选人的长期目标是成为翻译药物基因组学研究领域的独立资助的主要研究者。这一目标将通过基于临床和转化科学奖（CTSA）/药物基因组学研究网络（PGRN）的共同指导、合作以及本申请中概述的实践和教学机制来实现。 机构环境：西奈山医学院遗传学和基因组科学系（MSSM）是一个混合基础科学和临床部门，在转化遗传学和基因组科学方面提供广泛的教学，研究和临床服务计划。 MSSM基因组学和多尺度生物学研究所是完成现代基因组学研究所需的所有设备和计算支持的中心资源。 因此，MSSM的机构环境是正确执行本申请中概述的研究的理想选择。 研究项目：氯吡格雷和阿司匹林双重抗血小板治疗（DAPT）是急性冠脉综合征（ACS）患者和/或接受经皮冠状动脉介入治疗（PCI）患者的标准治疗，但是，通常观察到血小板抑制和临床应答的个体间差异很大。细胞色素P450- 2C 19（CYP 2C 19）是参与氯吡格雷生物活化的关键酶，携带CYP 2C 19功能丧失等位基因的患者治疗疗效降低，严重不良心血管事件风险增加。 然而，CYP 2C 19仅占氯吡格雷反应变异性的约12%。 拟议的研究项目将使用全外显子组测序和全基因组基因分型在精心挑选的极端表型队列DAPT治疗ACS/PCI患者，以确定新的遗传变异，这可能有助于将遗传指导的抗血小板治疗纳入常规介入心脏病学实践，以获得更个性化和更有效的护理。 识别额外的基因和变异不仅会影响个体化抗血小板治疗的使用，而且可以为其他药物和药物的药物基因组学研究提供基准。